Preventing diabetes . . . and other storiesBMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o77 (Published 20 January 2022) Cite this as: BMJ 2022;376:o77
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Why do you report the latest vitamin D trial from Finland in such an uninformed, unscientific way: “no benefit”? (1) Of course there will be no benefit from a supplement if the study group isn’t deficient of that supplement. The participants in this trial had adequate vitamin D blood levels (75 nmol/l) (2). In the UK, on the other hand, such a trial would most likely have shown a significant benefit for many diseases, especially where vitamin D-blood levels are particularly low, as in cancer. Cancer survival was significantly improved in RCTs with supplements (3,4).
The average Scot has blood level of 37 nmol/l (5), the average Finn 65 nmol/l. This is due to 15 years of effective food fortification, a wise preventative action by Finnish public health services. (6)
(By-the-way, Finland also has excellent Covid survival figures. (7))
(1) BMJ 2022/;376:o77
Competing interests: No competing interests